Skip to main content
OpenTrials
Completed

NCT Number: NCT05711810

Medicine-induced Cardiac Hemodialysis on COVID-19

The clinical trial studies the human pathogen of SARS-CoV-2, with a specificity in the circulating Spike 2 protein in the human system. The clinical trial hypothesizes that SARS-CoV-2 human pathogen arises from immune attacks, underlying the severe physiological symptoms that can be lethal. It further hypothesizes that the vaccines do not deal with the Spike 2 protein that causes the immune attacks.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Severe Acute Respiratory Syndrome-related Coronavirus Coronaviridae Infections Coronavirus Infections Infection Viral Infections Myocarditis Allergic Nidovirales Infections RNA Virus Infections Renal Dialysis Respiratory Tract Diseases Respiratory Tract Infections Severe Acute Respiratory Syndrome Vaccines Virus Diseases

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 4

Primary location

Residential Address

Chongqing, Chongqing Municipality, 402762, China

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • No mRNA vaccinated poisoning have been included currently, but scientific evidence suggest the methods of vaccination are irrelevant to the conditions. It is theorized that the more advanced the vaccine production technology, the deeper the poisoning.

Exclusion criteria

  • healthy individuals with no myocarditis or unvaccinated without infection by SARS-CoV series
  • persons with diabetes (Paxlovid and PrEP treatments can be applied according to availability)

Treatment and study plan

Nifedipine 30 MG

Drug

Due to initial availability of drugs and the intensities of the patient's symptoms, Nifedipine was used for initial intervention in preventing acute myocarditis from happening.

Other names: Nifedipine Control-release Tablets

Kangzhu BPCB0A-3A

Diagnostic Test

The diagnostic test has been used to confirm objective parameters to guide the intervention drug dosages and accessing the risks in sudden death and long term adverse effects.

Other names: Heart Monitor

Low Mobility

Behavioral

The behavioral intervention aimed at reducing the risks of sudden and strong blood flows in the patient's system.

Enalapril Maleate 10Mg Tab

Drug

The intervention aims to reduce the vein flows in Diastolic Blood Pressure, and the risks in blood clot formation and internal vein scratch bleeding.

Lansoprazole 30Mg Ec Cap

Drug

The intervention aims to server the allergy-inducing proteins to induce renal hemodialysis.

Metoprolol succinate

Drug

Metoprolol Succinate is used to control the cardiac artery flow amounts and stabilize the patient's heart rate.

Coenzyme Q10

Dietary Supplement

200 mg per day is used for supplement with the cardiac interventions.

d-alpha tocopherol acetate

Dietary Supplement

The 268 mg twice per day dietary healthcare is the patient's usual daily use.

Omega-3

Dietary Supplement

The 900 mg twice per day dietary healthcare is the patient's usual daily use.

Duloxetine Hydrochloride 20 MG Oral Capsule, Delayed Release

Drug

Duloxetine hydrochloride is used for the patient's neurodiverse conditions.

Other names: Neurodiverse

Superoxide Dismutase

Drug

Superoxide Dismutase is used to substitute the missing of antiviral drugs.

Primary outcomes

  1. Heart Rate

    Time frame: 1 day

    The heart rate is monitored daily, and the primary goal is to stabilize the patient's heart rate.

  2. Electrocardiogram

    Time frame: 20 days

    Electrocardiogram reflects the blood pressure management on the patient's health outcome and potential risks.

  3. Platelet Distribution

    Time frame: 10 days

    Platelet distribution is measured to determine the viral induced blood-borne pathogen in the physiological responses of the patient.

  4. Mean Platelet Volume

    Time frame: 10 days

    MPV is measured to determine the risks in blood clot and internal vein scratches in the patient.

  5. Eosinophil Absolute Number

    Time frame: 10 days

    Eosinophil Absolute Number is measured to determine the intensities of infection in the patient.

  6. Basophil Absolute Number

    Time frame: 10 days

    Basophil Absolute Number is measured on the counteraction of the patient's immune system integrities against the rapid acidification of the viral infection.

Secondary outcomes

  1. Cardiac Enzymes

    Time frame: 10 days

    Cardiac enzymes are measured to locate and eliminate the symptoms' causes, identify potential health risks, and to determine if subsidiary treatments are needed.

Sponsors and collaborators

Lead sponsor

Yang I. Pachankis

Indiv

Registry information

Official study title

Cardiac Transfer of SARS-CoV-2 Spike Protein Circulation Techniques - Medicine Induced Hemodialysis on "Vaccinated" Immune Attacks

Important dates

Study start
2023
Primary completion
2023
Study completion
2023
First posted
Feb 3, 2023
Registry last updated
Feb 3, 2023

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.